Targeted drugs for the treatment of lung cancer are mainly targeted drugs for non-small cell lung cancer, as follows: i. Targeted drugs for sensitive epidermal growth factor receptor gene mutations, such as gefitinib and erlotinib. Targeted drugs for the presence of sensitive epidermal growth factor receptor mutations and T790M mutations, such as oxitinib; ii. Targeted drugs for ALK positivity, such as crizotinib; iii. Targeted drugs for vascular epithelial inhibition, such as bevacizumab; these targeted drugs have good efficacy in clinical application, and the application needs to strictly grasp the indications.